Abstract
The cardinal characteristics of Parkinson disease (PD) include resting tremor, rigidity, and bradykinesia. Patients may also develop autonomic dysfunction, cognitive changes, psychiatric symptoms, sensory complaints, and sleep disturbances. The treatment of motor and non-motor symptoms of Parkinson disease is addressed in this article.
MeSH terms
-
Amantadine / therapeutic use
-
Antiparkinson Agents / therapeutic use*
-
Catechol O-Methyltransferase Inhibitors
-
Cognition Disorders / drug therapy
-
Corpus Striatum / drug effects
-
Corpus Striatum / physiopathology
-
Digestive System Physiological Phenomena / drug effects
-
Dopamine Agonists / adverse effects
-
Dopamine Agonists / therapeutic use
-
Enzyme Inhibitors / therapeutic use
-
Humans
-
Hypotension, Orthostatic / drug therapy
-
Levodopa / therapeutic use
-
Mental Disorders / drug therapy
-
Monoamine Oxidase Inhibitors / therapeutic use
-
Motor Activity / drug effects
-
Movement Disorders / drug therapy*
-
Movement Disorders / physiopathology
-
Neurons / drug effects
-
Parkinson Disease / drug therapy*
-
Parkinson Disease / physiopathology
-
Sleep Wake Disorders / drug therapy
-
Substantia Nigra / drug effects
-
Substantia Nigra / physiopathology
Substances
-
Antiparkinson Agents
-
Catechol O-Methyltransferase Inhibitors
-
Dopamine Agonists
-
Enzyme Inhibitors
-
Monoamine Oxidase Inhibitors
-
Levodopa
-
Amantadine